3 Houston innovators to know this week

Who's who

Meet this week's Houston innovators to know. Courtesy photos

It's safe to say most Houstonians have been glued to their TVs watching the Houston Astros in the World Series, but the city never sleeps on innovation news. And, one of this week's who's who of Houston innovation even has a World Series-worthy technology.

Here are this week's Houston innovators to know.

Patrick Lewis, co-founder of BBL Ventures

Patrick Lewis co-founded BBL Ventures that helps connect energy companies to startups that have innovative technology solutions for their pain points. Courtesy of Patrick Lewis

On last week's episode of the Houston Innovators Podcast, Patrick Lewis, co-founder of BBL Ventures, with his 25-year career in tech investing, took the mic to discuss Houston innovation, the energy tech industry, and BBL's progress with matchmaking big corporations and the startups that can help them stay competitive.

"At our core, we're an investment firm, but our mission statement is to be the innovation partner for the energy and natural resources industry," Lewis says on the podcast. Read more.

Brian DiPaolo, the chief technology officer of Accudata Systems

Through a partnership between two Houston companies, installing breast cancer screening technology is easier than ever. Courtesy of Acudata Systems

It's National Breast Cancer Awareness Month, and the demand for access to detection facilities is rising. Two Houston companies joined forces to help optimize detection.

Brian DiPaolo, the chief technology officer of Accudata Systems, along with Solis Mammography announced a new partnership with the creation of Center-in-a-Box, a technology solution that supports the rapid deployment of breast screening and diagnostic service. Combining IT design, engineering, equipment installation, and go-live support into one full-service package, Center-in-a-Box is forecasted to grow Solis by approximately 30 to 60 new mammography centers within the next 24 months.

"What differentiates Accudata is the services we provide," says DiPaolo. "From procurement and project management to design, installation, and ongoing support, Accudata is a one-stop shop for turning up a new site quickly." Read more.

Ben Fairchild, founder of Fairchild Sports Performance

Ben Fairchild is in the business of keeping athletes — from professionals to amateurs — in top shape. Courtesy of FSP

Sports technology is a burgeoning business and Ben Fairchild, founder of Fairchild Sports Performance, sees the value for its clients. Fairchild has created an app that allows users to stay in shape and access training from anywhere. This has been especially helpful for Fairchild's MLB athletes, which includes World Series athletes George Springer, right fielder for the Houston Astros, and Anthony Rendon, third baseman for the Washington Nationals,

"The FSP app is for anybody who has a body," Fairchild says. "We want to find solutions for long-term health and fitness challenges for people of all walks of life." Read more.

Through a partnership between two Houston companies, installing breast cancer screening technology is easier than ever. Getty Images

Houston tech company is helping to scale breast cancer screening using IT solutions

tech detection

With October being National Breast Cancer Awareness Month, two Houston companies are working to provide a fast and accurate diagnostic solution.

Accudata Systems and Solis Mammography announced a new partnership with the creation of Center-in-a-Box, a technology solution that supports the rapid deployment of breast screening and diagnostic service. Combining IT design, engineering, equipment installation, and go-live support into one full-service package, Center-in-a-Box is forecasted to grow Solis by approximately 30 to 60 new mammography centers within the next 24 months.

Brian DiPaolo, the chief technology officer of Accudata Systems, tells InnovationMap that the product side of the solution includes equipment for a healthcare clinic, network and security infrastructure, as well as computers, tablets, phones, printers, scanners, and more.

"What differentiates Accudata is the services we provide," says DiPaolo. "From procurement and project management to design, installation, and ongoing support, Accudata is a one-stop shop for turning up a new site quickly."

According to a news release, there is a great demand to provide more centers nationwide, Solis saw the need for innovation and a cost-effective solution and turned to Accudata for assistance. In partnership with Solis, Accudata created a full-service solution for the IT design, equipment, and deployment of one clinic.

"Accudata identified the business challenge centered around people, processes, and products," says DiPaolo. "Solis was unable to scale quickly, limited resources could not provide adequate support, and they did not have the necessary project management and service delivery capabilities. Procurement from different vendors and manufacturers was difficult to manage, and the current network architecture made the process of spinning up new sites difficult and time-consuming."

DiPaolo tells InnovationMap that the company assists Solis when it's time to build out a new clinic or renovate an existing site, first performing a wireless survey to figure out the size of the clinic (small, medium, or large) and the equipment needed. Once this step is complete and the team understands the need, Accudata can begin the process of setting up the equipment in their lab before shipping it to the site and completing the deployment. The total turnaround time from purchase to clinic go-live is just three weeks.

The partnership creates a powerful match. Accudata Systems, founded in 1982 by Rich Johnson and Terry Dickson, is one of the largest IT integrators in the United States with 136 Houston-based employees, as well as a few in San Antonio and Austin and 30 in Dallas. Solis Mammography is the nation's largest independent provider of breast screening and diagnostic services with more than 50 centers in Texas, Arizona, Ohio, North Carolina, Pennsylvania, Washington, D.C, Maryland, and Virginia.

"According to the World Health Organization, breast cancer is the most frequent cancer among women, impacting 2.1 million women each year," says Solis Chief Information Officer Guhan Raghu in a news release. "Breast cancer rates are increasing in nearly every region globally, making the screening and diagnostic services Solis provides ever more vital to early diagnosis and treatment. The Center-in-a-Box IT solution developed with Accudata allows Solis to rapidly address mammography needs across the United States and further fulfill our promise to help women achieve and maintain breast health and peace of mind."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hardtech accelerator names 8 founders to 2026 cohort

hardtech fellows

Hardtech-focused organization Activate has named 50 new members to its 2026 cohort of scientists, which includes eight startups joining Activate Houston.

Activate aims to support scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years.

This year's fellows represent 41 companies from 22 U.S. cities and 11 states.

“This cohort clearly demonstrates that the next industry-defining companies won't choose between modern technology and deep science; they'll be built by combining both,” Cyrus Wadia, CEO of Activate, said in the announcement. “These are the scientists and engineers turning our most urgent global challenges into the companies that will deliver a more sustainable future.”

The Houston fellows are working across the energy, space, AI infrastructure and agriculture sectors. They include:

  • Sophie Clare Broun, founder of Anning Corporation, which is producing clean hydrogen by stimulating naturally occurring geologic deposits
  • Kathy Andersen, founder of Brint Tech, which builds optical sensing systems that quantify hydrogen for infrastructure operators
  • Dorsa Talebi, founder of Kinetiq Drive, which builds rare-earth-free, contact-free electric motors with wireless rotors for small appliances and heavy industry alike
  • Neethu Pottackal, founder of Nivera, which is developing natural, edible coatings made from agricultural byproducts to reduce food waste and extend the shelf life of fresh food
  • Jonathan Huffman, founder of Orbital Arc, which is shrinking spacecraft propulsion to a microchip powerful enough for deep space
  • Tim Lee, founder of Renesin, which develops advanced materials for faster, more efficient AI hardware
  • Joshua Livingston, founder of Selerra Separations, which is developing high-performance membranes that cut the cost and energy consumption of water treatment
  • Wenli Jiang, founder of SwieNitro Recovery, which is developing technology that converts nitrogen-rich waste streams into valuable fertilizer

"Home to the largest concentration of engineers in the United States and a dense ecosystem of Fortune 100 and Fortune 500 companies, Houston is uniquely positioned for scientists tackling large-scale industrial challenges. Activate Houston fellows are connected to the city's deep networks in energy, chemicals, and materials," Activate said in the announcement.

Activate named its inaugural Houston cohort in 2024. It has other hubs in Boston, New York, and Berkley, California—where Activate is headquartered. The organization also offers a virtual and remote cohort, known as Activate Anywhere. Nationally, it has supported 346 fellows and 276 companies since 2015.

Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion. The latest cohort is Activate Houston's third. Read more about the last year's cohort here.

Rice, Houston Methodist award $90K for cancer research projects

seed grants

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked.

“We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said in a news release. “Together, we can achieve translational excellence.”

The projects

Chemotherapy is one of the most effective cancer treatments, but it can be hard on the body. The human body doesn’t like being injected with radioactive material, especially the skin around the injection point, which can become extremely irritated. For patients in long-term treatment, the skin irritation can be more than just a bother; it can lead to infections that are dangerous to a compromised immune system.

Angel A Marti, a professor of chemistry at Rice University, and Biana Godin, an associate professor of nanoscience at Houston Methodist Research Institute, are experimenting with metal nanoclusters as a way to block radiation at the injection site. The nanocluster could be applied in a cream or a gel on the skin, serving as a type of shield against the harsh radioactive material.

Meanwhile, Yuan Ma, an assistant professor of chemistry at Rice, and Shu-Hsia Chen, a professor of immunology at Houston Methodist Research Institute, are working with m6A. Discovered in the 1970s, m6A is the most prevalent chemical modifier found in mRNA in mammals. It is prevalent in many cancers, including leukemia.

Ma and Chen are working on measuring the amount of m6A in leukemia to see if it can determine the most effective cancer treatments. The team is also experimenting with ways to shut off m6A to see if it makes current leukemia treatments more effective.

Progress from SynthX

SynthX was first launched in April 2024 to turn research from Rice and Houston Methodist into real-world cancer treatments. Within a year, the center had secured $1.5 million in grant money to work on crossing the blood-brain barrier in brain cancer treatments. These latest awards show that SynthX Center continues to bridge the worlds of research and clinical practice.

“This collaboration reflects a shared commitment to team science in cancer research,” Daniela Matei, the director of the Houston Methodist Neal Cancer Center, added in the release. “These are the types of translational and pioneering projects that lead to transformation in patient care.”'

The SynthX Center awarded $90,000 in seed grants to three teams in 2025 and $80,000 to three teams in 2024.

Tesla self-driving mode wasn't to blame in Houston-area crash, report suggests

Tesla news

Federal safety investigators looking into a runaway Tesla that killed a grandmother in her home say the driver had pressed the accelerator to full speed, suggesting the vehicle's self-driving software was not to blame.

The driver had told police that he had the self-driving software turned on, but a report from the National Transportation Safety Board concluded that he had actually overridden that feature when he pushed hard on the pedal. Moments later the Tesla Model 3 raced down a residential street in Katy, Texas, at highway speeds, slammed into a brick home and killed a 76-year-old woman standing in the front room.

The crash last month drew national attention because Tesla CEO Elon Musk is seeking to reassure the public its self-driving feature is safe as he prepares to turn hundreds of thousands of Teslas already on the road into fully automatic vehicles and begin selling two-seated Cybercabs missing steering wheels and pedals.

The crash came two months after officials at a separate federal agency, the National Highway Traffic Safety Administration, announced it was elevating a 2024 investigation of the self-driving feature to new “engineering analysis” level, raising the possibility of a recall of 3.2 million Tesla vehicles.

That NHTSA probe was triggered by crashes where the self-driving feature failed to alert drivers to take control in fog and other poor visibility conditions.

The agency opened an investigation last year into 58 incidents in which Teslas reportedly violated traffic safety laws while using self-driving technology, leading to more than a dozen crashes and fires and nearly two dozen injuries.

Separate from the National Transportation Safety Board, NHTSA is also looking into the Tesla house crash in Texas, one of 46 “special crash” investigations of Tesla's self-driving or driver-assistance technology in the past decade, according to the agency’s records. In more than a dozen of those crashes, at least one person — a driver, passenger or pedestrian — was killed.

Tesla had originally called its driver assistance software Full Self-Driving, or FSD, but auto experts and regulators complained it was misleading because drivers must always keep their eyes on the road and be ready to take over at any time.

The company has since changed the name to Full Self-Driving (Supervised).

Video of the Katy, Texas, accident shows the Tesla traveling at more than 70 mph (112.65 kilometers per hour), jumping a curb then tearing across a lawn before crushing through a brick wall of a home. A woman standing feet away, Martha Avila, was found amid piles of crumbling plaster, split beams and bits of furniture and rushed to a hospital but died.

Sales of Tesla cars still haven't recovered fully from boycotts last year over Musk's political stands, but the stock is rising anyway as he has successfully shifted attention away from the sales figures. He says they matter less now that the company is on the cusp of major technological advances, such as turning Teslas into hands-free vehicles and having its Optimus robots take over for humans for tasks at home and work.

Tesla stock has risen 22% in the past year and is currently trading at 170 times expected annual earnings compared to 20 for the S&P 500.

For its second-quarter financial results, financial analysts surveyed by FactSet expect earnings per share will barely budge — 32 cents versus 33 cents a year earlier — continuing a sixth quarter streak of flat or falling profits.

View All Listings